REDUCTION OF DIALYZER FIBRIN DEPOSITION WITH SULPHINPYRAZONE

Abstract

To determine whether sulfinpyrazone reduces thrombus formation within artificial kidneys, dialyzer 125I-fibrinogen and platelet and fibrinogen levels during dialysis were compared during a non-treatment control period and while patients were receiving sulfinpyrazone. Mean fibrin deposition within the dialyzers, measured as gram .times. 10-3 of clottable fibrinogen, was significantly less during sulfinpyrazone treatment (2.5) than during the control period (5.3). Arterial blood platelet counts and plasma fibrinogen levels during dialysis were higher on treatment despite similar predialysis values during control and treatment periods. Sulfinpyrazone reduces fibrin formation within artificial kidneys. Since the reduction in deposition of fibrin alone is insufficient to explain the higher plasma fibrinogen levels during treatment with sulfinpyrazone, this therapy may reduce fibrinogen consumption within the patient during hemodialysis.